Blood test could predict esophageal cancer return

NCT ID NCT05704530

Recruiting now Knowledge-focused Sponsor: Universitaire Ziekenhuizen KU Leuven Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is looking at whether a blood test (liquid biopsy) can find tiny bits of cancer DNA left behind after treatment for esophageal cancer. Researchers will collect blood samples from 248 patients before, during, and after standard treatment. The goal is to see if this test can improve cancer staging and predict if the cancer will come back.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: blood sample (liquid biopsy for ctDNA)
What this could lead to: If successful, this could lead to a more accurate way to stage esophageal cancer and predict if the cancer will come back after treatment.
What could go wrong: This is an early-stage observational study, so it may not prove that liquid biopsies improve outcomes. The test might not be sensitive enough to detect all cases of residual cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal adenocarcinoma esophageal cancer Esophageal Neoplasms esophageal squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGEAL CANCER

Contacts and locations

Locations

AZ Delta
RECRUITING

Roeselare, Belgium
UZ Gent
RECRUITING

Ghent, Belgium
UZA
RECRUITING

Antwerp, Belgium
UZLeuven
RECRUITING

Leuven, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.